Track the companies that matter to you. It's FREE! Click one of these fan favorites to get started: Apple; Google; Ford.



FDA Concerns Are the Least of These Drugs' Worries

Watch stocks you care about

The single, easiest way to keep track of all the stocks that matter...

Your own personalized stock watchlist!

It's a 100% FREE Motley Fool service...

Click Here Now

The race to develop a highly effective cholesterol lowering therapy for patients unable to take statins continues, despite some setbacks. A recent revelation prompted a little panic selling, but a bigger event is looming around the corner. There are much bigger concerns for the new drug class that revolve around an unrelated trial with Merck's  (NYSE: MRK  )  market stage cholesterol therapies. 

Late last week, investors noticed a particularly disturbing piece of news in Sanofi's (NYSE: SNY  ) annual SEC filing. Sanofi and partner Regeneron  (NASDAQ: REGN  ) "have been advised by the FDA that it has become aware of neurocognitive adverse events in the PCSK9 inhibitor class." The disclosure goes on to state that neurocognitive adverse events have been associated with the use of statins, but Sanofi doesn't know of any associated with its PCSK9 inhibitor, alirocumab. The agency also wants Sanofi and Regeneron to basically look into it, and consider including neurocognitive testing into subsets of patients in existing trials.

Although the statement seemed fairly benign, shares of Regeneron fell nearly 10% almost immediately after the news spread quickly over Twitter. Regeneron regained much of what it lost in the panic, as did competitor in the PCSK9 race Amgen (NASDAQ: AMGN  ) . Also investing heavily in PCSK9 therapy is Pfizer (NYSE: PFE  ) , which was relatively unaffected by the news.

REGN Chart

REGN data by YCharts

A fuzzy feeling
As far as adverse events go, the reports of cognitive impairment that the FDA noted in a consumer report updated earlier this year are minor. Other rarely reported statin issues in the agency's update include risk of diabetes and liver injury.

Apparently the regulator has been following rare cases of cognitive impairment that span all statin products for some time now. Patients affected report feeling "fuzzy" or unfocused. Luckily, the feelings are reversible following cessation of treatment.

A more serious concern
While adverse events of any nature should be a cause for concern, the knee-jerk response to such a benign statement illustrates the heavy anxiety surrounding this new drug class. I think the largest risk factor to companies developing PCSK9 therapies is skepticism surrounding the association of lower LDL cholesterol -- the bad kind -- and risk of heart attack or stroke.

At the moment, the FDA is willing to accept reductions in LDL cholesterol as a surrogate endpoint for long-term cardiovascular benefit. This means that companies like Amgen and Sanofi won't be required to monitor patients for years longer than planned.

Unfortunately for the companies, those rules aren't set in stone. If the agency changes its mind, drugmakers will need to pay for lengthy cardiac outcome studies to determine whether or not patients receiving PCSK9 injections actually suffer heart attack or stroke at significantly lower rates.

An important release
Last November, deputy director of the FDA's division of metabolism and endocrinology Eric Colman told Bloomberg that the agency is waiting on results of an extremely long trial, titled Improve-it. The trial, initiated in 2005, is comparing Merck's Vytorin (ezetimibe/simvastatin) to Zetia (ezetimibe). While Zetia is proven to lower LDL cholesterol in patients who can't take statins, its effect on overall risk of cardiac events is still considered unproven.

Since PCSK9 injections are also intended for patients that can't take statins, the results of this trial, expected this September, might be the event of the year. If ezetimibe doesn't significantly lower the risk of cardiac events, the fallout from Sanofi's recent disclosure may pale in comparison.

In 2008, the controversial Enhance study suggested that the combination of simvastatin and ezetimibe did not result in significant differences in thickness of inner-arterial walls compared to simvastatin alone. It's hardly a death-blow for non-statin LDL cholesterol lowering therapies, but it doesn't inspire confidence either. Pfizer has already hedged its bet on its PCSK9 candidate by initiating cardiac outcomes trials. This September Pfizer's competitors may wish they did as well.

Stop worrying about the day to day
As every savvy investor knows, Warren Buffett didn't make billions by betting on half-baked stocks. He isolated his best few ideas, bet big, and rode them to riches, hardly ever selling. You deserve the same. That's why our CEO, legendary investor Tom Gardner, has permitted us to reveal The Motley Fool's 3 Stocks to Own Forever. These picks are free today! Just click here now to uncover the three companies we love. 

Read/Post Comments (0) | Recommend This Article (2)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2869915, ~/Articles/ArticleHandler.aspx, 9/5/2015 6:18:22 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Cory Renauer

Cory is a long-term minded analyst mainly focused on the biotechnology and pharmaceuticals. He genuinely enjoys cutting through the industry's complexities to help everyday investors make better decisions. You can contact Cory on Twitter @coryrenauer

Today's Market

updated 9 hours ago Sponsored by:
DOW 16,102.38 -272.38 -1.66%
S&P 500 1,921.22 -29.91 -1.53%
NASD 4,683.92 -49.58 -1.05%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

9/4/2015 4:01 PM
MRK $51.59 Down -1.06 -2.01%
Merck & Co., Inc. CAPS Rating: ****
REGN $499.99 Down -8.52 -1.68%
Regeneron Pharmace… CAPS Rating: ***
SNY $48.45 Down -1.12 -2.26%
Sanofi (ADR) CAPS Rating: *****
AMGN $147.02 Down -2.21 -1.48%
Amgen CAPS Rating: ****
PFE $31.37 Down -0.52 -1.63%
Pfizer CAPS Rating: ****